Tumor Necrosis Factor News and Research

RSS

Thrombosis biomarker levels differ according to thrombolysis strategy

An early invasive strategy following thrombolysis for ST-segment-elevation myocardial infarction is associated with significant changes in the levels of inflammatory and thrombotic biomarkers, a substudy of the Norwegian study on district treatment of STEMI shows.

31 May 2012

Juvenile Arthritis patients may have difficulties achieving educational success

As children with juvenile idiopathic arthritis (JIA) grow into adulthood, disability due to disease may adversely affect their ability to achieve educational success. Findings published in Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR), suggest that functional disability impacts educational attainment, which is key to successful employment in adulthood.

31 May 2012

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

Abbott scientists and independent researchers will highlight the latest investigational research findings on HUMIRA (adalimumab) at the European League Against Rheumatism (EULAR) Congress in Berlin, Germany, from 6-9 June, 2012.

29 May 2012

New research reveals effective treatments for gastrointestinal conditions

New research being presented at Digestive Disease Week- (DDW) reveals effective treatments for a number of gastrointestinal conditions, which are often chronic and costly.

22 May 2012

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

New study findings presented today show that subcutaneous induction regimens of the anti-tumor necrosis factor (TNF)-alpha therapy SIMPONI (golimumab) induced clinical response in a majority of patients with moderately to severely active ulcerative colitis (UC) who had previously failed or were intolerant to conventional agents.

22 May 2012

NCKU student receives Graduate/Postdoctoral Travel Award from ASBMB

Wan-Pei Su, a graduate student of Molecular Medicine at National Cheng Kung University (NCKU), southern Taiwan, has received a Graduate/Postdoctoral Travel Award from the American Society for Biochemistry and Molecular Biology (ASBMB) to attend the annual conference on Experimental Biology (EB) in San Diego in April 2012.

10 May 2012

High-dose glucocorticoids double risk of bacterial infections in children with JIA

Children with juvenile idiopathic arthritis have higher rates of bacterial infection requiring hospitalization, and use of high-dose steroids significantly increases that risk, according to research from the University of Alabama at Birmingham.

2 May 2012

High-dose steroids increase infection risk in children with juvenile idiopathic arthritis

Children with juvenile idiopathic arthritis (JIA) have higher rates of hospitalized bacterial infection than children without JIA according to an observational study appearing in Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR).

2 May 2012

Steroids still work better for patients with sciatica

Despite the great promise that injecting a new type of anti-inflammatory pain medicine into the spine could relieve the severe leg and lower back pain of sciatica, a Johns Hopkins-led study has found that the current standard of care with steroid injections still does better.

17 Apr 2012

New guidelines offer guidance on how and when to switch between RA drug classes

A trend toward more aggressive treatment in patients just starting to develop rheumatoid arthritis is among the most important changes in treatment guidelines for the disease, according to updated American College of Rheumatology recommendations published today in the journal Arthritis Care & Research. The trend may proceed from emerging opinions that joint damage caused by RA is irreversible, and that early, intensive therapy better preserves physical function, quality of life and capacity to work.

2 Apr 2012

Pfizer to present data on ADCs at AACR 2012

Pfizer Oncology will present data from a variety of preclinical and clinical studies of Pfizer's early-stage compounds, including data from Pfizer's investigational antibody-drug conjugate (ADC) portfolio and research evaluating several molecules targeting novel pathways that play a crucial role in basic cellular functions, at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago, IL, from March 31-April 4.

27 Mar 2012

Advances in Neuroimmune Biology explores maternal-fetal interactions

Fertility problems, recurrent miscarriages, and pregnancy complications can occur when maternal immunological tolerance of the fetus is impaired. G-rard Chaouat and colleagues from Inserm et Assistance Publique et Universit- Paris Sud Orsay, Hopital Antoine B-cl-re, Clamart Cedex, France, trace the evolution of the science of reproductive immunology to show how the current understanding of maternal-fetal tolerance/dialogue has developed, and its implications for the treatment of infertility disorders

22 Mar 2012

Hedgehog and mTOR pathway are active in esophageal cancer

Identification of a non-traditional pathway for spiriting a cancer-promoting protein into the cell nucleus points to a possible combination therapy for esophageal cancer and indicates a mechanism of resistance for new drugs that attack the Hedgehog pathway.

20 Mar 2012

Scientists track initial steps of type 1 diabetes mellitus

Scientists have taken a remarkably detailed look at the initial steps that occur in the body when type 1 diabetes mellitus first develops in a child or young adult.

17 Feb 2012

Incident malignancy four times higher among children with JIA

New research reports that incident malignancy among children with juvenile idiopathic arthritis (JIA) is four times higher than in those without the disease. Findings now available in Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR), suggest JIA treatment, such as tumor necrosis factor (TNF) inhibitors, does not necessarily explain the development of cancer in this pediatric population.

13 Feb 2012

Tailoring TB treatment based on a patient's genetic sequence

A gene that influences the inflammatory response to infection may also predict the effectiveness of drug treatment for a deadly form of tuberculosis.

8 Feb 2012

Duke team creates vaccine adjuvant of nanoparticles that target lymph nodes

Researchers at Duke University Medical Center have created synthetic nanoparticles that target lymph nodes and greatly boost vaccine responses, said lead author Ashley St. John, Ph.D., a researcher at Duke-NUS Graduate Medical School.

23 Jan 2012

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.

21 Jan 2012

RBC storage duration not associated with transfusion-related pulmonary complications

There is no difference in early measures of pulmonary function, immunologic status or coagulation status after fresh versus standard issue single-unit red blood cell (RBC) transfusion, according to a new study from the Mayo Clinic.

21 Jan 2012

New biomarkers can predict risk of kidney failure in patients with diabetes

Scientists at Joslin Diabetes Center have identified two novel markers that, when elevated in the blood stream, can predict accurately the risk of renal (kidney) failure in patients with Type 1 and Type 2 diabetes.

20 Jan 2012